Last update 02 Aug 2025

Anti-BCMA CAR T Cell Therapy (Shanghai Simnova Biotechnology)

Overview

Basic Info

Drug Type
CAR-T
Synonyms
B cell malignancies(Orna), CART-BCMA (Shanghai Simnova Biotechnology), SNC-102
+ [1]
Target
BCMA
Action
inhibitors
Mechanism
BCMA inhibitors(B-cell maturation protein inhibitors), Gene transference(Gene transference), T lymphocyte replacements
Therapeutic Areas
NeoplasmsImmune System DiseasesHemic and Lymphatic Diseases+ [1]
Active Indication
Relapse multiple myelomaB-Cell Malignant Neoplasm
Inactive Indication-
Originator Organization
Shanghai Simnova Biotechnology Co.,Ltd.
Active Organization
Shanghai Simnova Biotechnology Co.,Ltd.Orna Therapeutics, Inc.Orna Therapeutics, Inc.
Inactive Organization-
License Organization
Orna Therapeutics, Inc.Orna Therapeutics, Inc.
Shanghai Simnova Biotechnology Co.,Ltd.
Drug Highest PhasePhase 1
First Approval Date-
Regulation-
Login to view timeline

Related

1
Clinical Trials associated with Anti-BCMA CAR T Cell Therapy (Shanghai Simnova Biotechnology)
NCT05346198
/ Active, not recruitingPhase 1
A Phase I Clinical Trial to Evaluate CART-BCMA in Patients With Relapsed and/or Refractory Multiple Myeloma
100 Clinical Results associated with Anti-BCMA CAR T Cell Therapy (Shanghai Simnova Biotechnology)
Login to view more data
100 Translational Medicine associated with Anti-BCMA CAR T Cell Therapy (Shanghai Simnova Biotechnology)
Login to view more data
100 Patents (Medical) associated with Anti-BCMA CAR T Cell Therapy (Shanghai Simnova Biotechnology)
Login to view more data
100 Deals associated with Anti-BCMA CAR T Cell Therapy (Shanghai Simnova Biotechnology)
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Relapse multiple myelomaPhase 1
China
Shanghai Simnova Biotechnology Co.,Ltd.
12 Mar 2021
B-Cell Malignant NeoplasmPreclinical
United States
Orna Therapeutics, Inc.Orna Therapeutics, Inc.
25 Jun 2024
B-Cell Malignant NeoplasmPreclinical
China
Shanghai Simnova Biotechnology Co.,Ltd.
25 Jun 2024
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
NCT05346198 (ASH2023)
Phase 1
Relapse multiple myeloma
15
zeuvwvjgar(wyyzesvedu) = gvjmzcodnz ixcgfgqqvk (slyghdomed, 78.20% - 100.00)
View more
-
10 Dec 2023
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free